retatrutide trial results today eli lilly The biggest weight-loss result ever recorded in a Phase 3 just landed — and it changes the conversation. Lilly's (a "triple agonist") delivered an average 28.3% body-weight retatrutide peptide clinical trial results

Hair loss on GLP-1 can feel surprisingly upsetting

In an announcement of the study on the Vanderbilt website, lead author Khrysta Baig described this as a purely hypothetical scenario, but one that underscores that at current prices, these medications cannot be the only way or even the main way we address obesity as a society. In a more conservative estimate, Bhaig and coauthors consider a case where only about 10% of those eligible for obesity treatment opted for semaglutide, which would result in $27 billion in new costs

It is a GLP-1 receptor agonist, which means it mimics an incretin hormone in the body that helps regulate insulin secretion and appetite

10.1097/QAI.0000000000000551 46